RadIO: For Investigators

 A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

Change of Staff

Relevant registration forms to be uploaded on this page as soon as available. 

Study Documents

Links to the current protocol, patient information sheet, informed consent form are provided below. If there has been a recent amendment to the study please ensure you have R&D approval before using these documents.

Other documents (e.g. serious adverse event form and questionnaires) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the Radio Study Office.

Version Control Lists

The version numbers and dates of all documents currently used for the study are captured on a document version control list.

Case Report Form

The CRFs for this study will be listed on this page once available.  


The Study Guidance document will be uploaded on this page once available. 

Other Study Documents

The SAE Form and Questionnaires Booklet will be uploaded on this page once available. 


No publications currently.

News and Events

There are no current news or events for this study.

Contact Details

Chief Investigator

Professor Nicholas James                                          
The Institute of Cancer Research, London SW3 6JB 

Tel: 020 7153 5130 

RadIO Study Office

Trial Coordinator:  Ms Baljit Kaur & Anne-Marie Hodgkins
Trial Monitor:  Ms Davina Scott

Trial Management Team Leader:  Ms Sophia Magwaro
Trial Statistician:  Dr Wenyu Liu

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
B15 2TT


Telphone: +44 (0) 121 414 3793 
Fax: +44 (0) 121 414 2230



Emergency Randomisation  

0121 414 3793 or 0121 415 8544 *

Serious Adverse Event Reporting

Email to:



The University of Birmingham